Welcome to LookChem.com Sign In|Join Free

CAS

  • or

142801-55-6

Post Buying Request

142801-55-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

142801-55-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 142801-55-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,2,8,0 and 1 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 142801-55:
(8*1)+(7*4)+(6*2)+(5*8)+(4*0)+(3*1)+(2*5)+(1*5)=106
106 % 10 = 6
So 142801-55-6 is a valid CAS Registry Number.

142801-55-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl (S)-1-(methoxy(methyl)amino)-5-(3-(4-methoxy-2,3,6-trimethylphenylsulfonyl)guanidino)-1-oxopentan-2-ylcarbamate

1.2 Other means of identification

Product number -
Other names N-α-(t-butyloxycarbonyl)-N'-ω'-(4-methoxy-2,3,6-trimethylbenzenesulfonyl)-L-arginine-N,O-dimethylhydroxyamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:142801-55-6 SDS

142801-55-6Relevant articles and documents

Analysis of subpocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2

Duchêne, Dominic,Colombo, Elo?c,Désilets, Antoine,Boudreault, Pierre-Luc,Leduc, Richard,Marsault, Eric,Najmanovich, Rafael

, p. 10198 - 10204 (2014)

We studied the factors affecting the selectivity of peptidomimetic inhibitors of the highly homologous proteases matriptase and matriptase-2 across subpockets using docking simulations. We observed that the farther away a subpocket is located from the catalytic site, the more pronounced its role in selectivity. As a result of our exhaustive virtual screening, we biochemically validated novel potent and selective inhibitors of both enzymes.

Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology

Damalanka, Vishnu C.,Han, Zhenfu,Karmakar, Partha,O'Donoghue, Anthony J.,La Greca, Florencia,Kim, Tommy,Pant, Shishir M.,Helander, Jonathan,Klefstr?m, Juha,Craik, Charles S.,Janetka, James W.

, p. 480 - 490 (2019)

Matriptase and hepsin belong to the family of type II transmembrane serine proteases (TTSPs). Increased activity of these and the plasma protease, hepatocyte growth factor activator (HGFA), is associated with unregulated cell signaling and tumor progression through increased MET and RON kinase signaling pathways. These proteases are highly expressed in multiple solid tumors and hematological malignancies. Herein, we detail the synthesis and structure-activity relationships (SAR) of a dipeptide library bearing Arg α-ketobenozothiazole (kbt) warheads as novel inhibitors of HGFA, matriptase, and hepsin. We elucidated the substrate specificity for HGFA using positional scanning of substrate combinatorial libraries (PS-SCL), which was used to discover selective inhibitors of matriptase and hepsin. Using these selective inhibitors, we have clarified the specific role of hepsin in maintaining epithelial cell membrane integrity, known to be lost in breast cancer progression. These selective compounds are useful as chemical biology tools and for future drug discovery efforts.

INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES

-

Paragraph 0081; 0187, (2016/09/26)

The present invention generally relates to compounds that are useful for inhibiting one or more of hepatocyte growth factor activator, matriptase, hepsin, Factor Xa, or thrombin. The present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 142801-55-6